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This study was aimed to investigate the significance of 18F-FDG PET/CT in secondary hemophagocytic
lymphohistiocytosis (sHLH) patients. A total of 18 patients received 18F-FDG PET/CT scan at initial diagnosis. All
patients (18/18) had at least 3 organs involved, with increased FDG metabolism in different degrees. Fifteen cases
(15/18) had definite underlying diseases, including infections (IAHLH), rheumatosis (RAHLH), or malignancy
(MAHLH). The SUVmax of patients in MAHLH group was significantly higher than patients in IAHLH group or RAHLH
group (P = 0.015, P = 0.045). Furthermore, the SUVmax of patients in IAHLH group was significantly higher than
patients of RAHLH group (P = 0.043). Therefore, we concluded that 18F-FDG PET/CT may especially play important
role in differential diagnosis of sHLH.To the Editor
Secondary hemophagocytic lymphohistiocytosis (sHLH)
is a hyper-inflammatory clinical syndrome mainly caused
by severe infections, autoimmune inflammatory disor-
ders and malignancies, especially lymphoma [1-3]. Up to
date, very few data from the literature are available
regarding the role of 18F-FDG PET/CT in sHLH. In this
study, 18 of 50 patients with sHLH who were admitted
into our hospital between May 2007 and December 2010
underwent the examination (Table 1). The male-to-
female ratio was 1:1, and the median age was 35 years
(15-73). The diagnosis of HLH was made according to
HLH-2004 diagnostic guidelines [4,5], and the under-
lying diseases were confirmed by a series of pathogenesis
examinations including pathology, immunology, bacter-
ial culture and virus detection et al. The maximum stan-
dardized uptake values (SUVmax) used to measure the
level of FDG uptake were determined in all lesions [6].
All of the 18 patients had at least 3 organs involved, with
increased FDG uptake at different level, including 18
cases showing splenomegaly, 16 cases serous effusions,
16 cases lymphadenopathy, 13 cases bone lesions, 12* Correspondence: qhx9805@126.com; zbruce.zhang@gmail.com
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reproduction in any medium, provided the orcases pneumonia, 8 cases hepatomegaly, 5 cases brain
parenchymal or cerebroventricular lesions, 5 cases
cholecystitis, 4 cases myocardium lesions, and 2 cases
kidney calculi. There were also other organs involved,
such as larynx, muscles and adnexauteri. Fifteen
patients (15/18) had definite underlying diseases, and
were divided into three groups.,including Infection
Associated HLH (IAHLH, including EBV-HLH, n = 8),
Rheumatosis Associated HLH (RAHLH, n = 2), and
Malignancy Associated HLH (MAHLH, n = 5). The
SUVmax of patients in MAHLH group was signifi-
cantly higher than those of patients with IAHLH
(Mean 12.0 vs. 6.8, P = 0.015), and RAHLH (Mean
12.0 vs. 2.7, P = 0.045). Furthermore, the SUVmax of
patients with IAHLH was significantly higher than
that of patients with RAHLH (Mean 6.8 vs. 2.7,
P = 0.043). However, no significant difference in sur-
vival time was found between the three different
sHLH subtype according to Kaplan-Meier analysis
(P >0.05). In conclusion, 18F-FDG PET/CT may play
important role in differential diagnosis of sHLH, with
high SUV pointing toward underlying malignancy.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Characteristics of 18 sHLH patients
No. Age/ Sex Underlying disease Therapy Outcome Survival (month) Organs SUVmax






2 35/F Lymphoma (NK / T) The Hyper-CVAD regimen (1 cycle) Died of intracranial
hemorrhage
1.2 6 15.7
3 18/M Lymphoma (NK / T) The CHOP regimen(1 cycle) Died of acute hemorrhage
of gastrointestinal tract
0.3 7 14.6
4 56/M Lymphoma Hydrocortisone 100mg×5d Died of intracranial
hemorrhage
1.7 5 4.3
5 32/M Lymphoma Dex 10mg/d×3d Died of liver failure 0.3 10 13.3
6 37/F Sjögren's syndrome The COP regimen(3 cycle) CR >12 5 0.7
7 15/F UCTD The COP regimen (4 cycle) CR >45 3 4.6
8 21/F EBV infection HLH-2004 regimen (1 cycle) Died of acute hemorrhage
of gastrointestinal tract
1.7 7 6.6
9 17/M EBV infection Methylprednisolone 40 mg/d×24d CR >22 7 8.3
10 46/M EBV infection Dex 15mg/d×4d Died of septic shock 0.4 6 10
11 73/M EBV infection The COP regimen (7 cycle) Died of multi-organ failure 6 7 5.2
12 26/F CMV infection IVIG/HLH-2004 regimen (1 cycle)!
The CHOP regimen(2 cycle)
CR >24 6 9
13 24/F CMV infection The COP regimen (7 cycle) Died of respiratory failure 2.2 5 4.2
14 69/F MRSH infection The COP regimen (2 cycle) Died of respiratory failure 2.0 6 5.2
15 62/F Fungal Infection The COP regimen (7 cycle) stable >8 4 5.8
16 44/F Malignant tumour? Methylprednisolone 40 mg/d×5d Died of multi-organ failure 0.4 8 7.7
17 56/M Lymphoma? The CHOP regimen (2 cycle)!
Splenectomy!The Hyper-CVAD
regimen (1cycle)
stable >13 6 5.7
18 18/M indefinite HLH-2004 regimen (1 cycle) Died of intracranial
hemorrhage
0.2 3 4.2
HLH-2004, dexamethasone, etopside and Ciclosporin A; CHOP, cyclophosphamide, adviamycin, vincristine and prednisolone; COP, cyclophosphamide, vincristine
and prednisone; Hyper-CVAD, cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate and cytarabine; DEX, dexamethasone; CR, complete
response; UCTD, undifferentiated connective tissue disease; EBV, Epstein-Barr virus; CMV, cytomegalovirus; MRSH, methicillin-resistant Staphylococcus hominis.
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